NCT06568172 2026-04-16
Testing the Addition of an Immunotherapy Drug, Cemiplimab (REGN2810), Plus Surgery to the Usual Surgery Alone for Treating Advanced Skin Cancer
National Cancer Institute (NCI)
Phase 3 Recruiting
Clinical Trials
16 trialsNCT07530887 2026-04-15
NORMA-2
The Netherlands Cancer Institute
Phase 3 Recruiting
NCT02821013 2026-04-14
STOP-GAP
Canadian Cancer Trials Group
Phase 3 Recruiting
NCT02506153 2026-04-13
Physician/Patient Choice of Either High-Dose Recombinant Interferon Alfa-2B or Ipilimumab, Versus Pembrolizumab in Treating Patients With Stage III-IV High Risk Melanoma That Has Been Removed by Surgery
National Cancer Institute (NCI)
Phase 3 Active not recruiting
NCT03271372 2026-04-13
ADAM
University of Washington
Phase 3 Active not recruiting
NCT06743126 2026-04-13
SUPRAME
Immatics US, Inc.
Phase 3 Recruiting
NCT04099251 2026-04-09
CheckMate76K
Bristol-Myers Squibb
Phase 3 Active not recruiting
NCT06585410 2026-04-08
Study of Intralesional Cemiplimab in Adult Patients With Early Stage Cutaneous Squamous Cell Carcinoma
Regeneron Pharmaceuticals
Phase 3 Recruiting
NCT04657991 2026-04-07
A Clinical Trial of Three Study Medicines (Encorafenib, Binimetinib, and Pembrolizumab) in Patients With Advanced or Metastatic Melanoma
Pfizer
Phase 3 Active not recruiting
NCT05662202 2026-04-03
Study to Evaluate the Safety, Tolerability and Efficacy of BF-200 ALA (Ameluz®) in the Field-directed Treatment of Actinic Keratosis (AK) on the Extremities and Neck/Trunk With Photodynamic Therapy (PDT) Using a RhodoLED Lamp
Biofrontera Inc.
Phase 3 Active not recruiting
NCT05727904 2026-04-03
Study to Investigate Lifileucel Regimen Plus Pembrolizumab Compared With Pembrolizumab Alone in Participants With Untreated Advanced Melanoma.
Iovance Biotherapeutics, Inc.
Phase 3 Recruiting
NCT06470451 2026-04-03
FLASH2
Soligenix
Phase 3 Recruiting
NCT06500455 2026-04-03
Testing Longer Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients With Cancer That Has Spread to the Brain
NRG Oncology
Phase 3 Recruiting
NCT03969004 2026-03-27
Study of Adjuvant Cemiplimab Versus Placebo After Surgery and Radiation Therapy in Patients With High Risk Cutaneous Squamous Cell Carcinoma
Regeneron Pharmaceuticals
Phase 3 Active not recruiting
NCT05907122 2026-03-27
A Study to Evaluate Similarity of ABP 206 Compared With OPDIVO® (Nivolumab) in Subjects With Resected Melanoma
Amgen
Phase 3 Completed
NCT06135415 2026-03-25
TirbAKare
Almirall, S.A.
Phase 3 Completed